EN DE
Watch Rocket Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rocket Pharmaceuticals Inc (RCKT) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Rocket Pharmaceuticals Inc stock $1.27, price $2.39, that is 46.8% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

RP Rocket Pharmaceuticals Inc logo Thin data Nov 7, 2026

Rocket Pharmaceuticals Inc

RCKT · US
Very expensive, weak quality

Our calculation puts a fair price 47% below what the stock costs today.

Low debt
Ranks above peers (5/8)
Insiders sold $639,804 (6M)
Fair value $1.27 · Strongly overvalued (−46.8%)
Quality 37/100
Negative free cash flow
Narrow moat 8/100 · thin data
Downbeat coverage
Thin data
Watch Rocket Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$36.58 $2.18 Fair Value $1.27 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $2.18 – $36.58 · fair‑value band $0.8400 – $1.59 · the $2.39 price screens above the $1.27 fair value. As of Nov 7, 2026.

Follow Rocket Pharmaceuticals in your weekly email

Every Wednesday you see whether Rocket Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.

Show moreShow less

It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.

It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).

It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University.

Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Stock analysis

Rocket Pharmaceuticals Inc (RCKT) currently trades at $2.39, while our model-based Fair Value estimate is $1.27, 47% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.8400 (bear) to $1.59 (bull), the price of $2.39 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Rocket Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$223M in FY2025.

Key figures

Market cap $273M Micro · EPS (TTM) $−0.1700 · Return on equity −4.8% · Return on assets (EBIT) −48.2% (5-year average) · Free cash flow −$190M · Net cash $52.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −47%, RCKT screens richer than that median.

Fair Value models

Bear $0.8400 Fair Value $1.27 Bull $1.59
Price $2.39 · Downside -46.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.8400 $1.27 $1.59 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.8400 $1.27 $1.59 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 23
Do the profits arrive as real cash?
Financial strength 68
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 25
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors sold shares worth $639,804 and none bought.

  • SaleMartin WilsonGeneral Counsel8× since Nov 18, 2025: 98,786 shares, avg. $3.38$334,361Sep 11, 2026
  • SaleGaurav ShahCEO8× since Nov 18, 2025: 90,496 shares, avg. $3.16$285,855Aug 18, 2026
  • SaleSarbani ChaudhuriOfficer2× since May 7, 2026: 22,351 shares, avg. $3.77$84,230Aug 11, 2026
  • SaleChristopher James StevensChief Operating Officer36,658 shares at $3.50$128,303Aug 11, 2026
  • SaleJohn MilitelloOfficer5× since Nov 18, 2025: 7,208 shares, avg. $3.28$23,676May 19, 2026
  • BuyElisabeth BjorkDirector10,000 shares at $3.44$34,400Jan 2, 2026
  • SaleJonathan David SchwartzOfficer2,545 shares at $2.98$7,584Nov 18, 2025

Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

RCKT screens overvalued: fair value 47% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (84 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Rocket Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −46.8% · Above median
Profitability
Return on assets −67.5% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.99× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs RCKT
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs RCKT
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs RCKT
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs RCKT
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs RCKT
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs RCKT
argenx SE ARGX $927.21 $908.40 −2% vs RCKT
CSL Limited CSL A$202.04 A$183.04 −9% vs RCKT
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs RCKT
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs RCKT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rocket Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rocket Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/RCKT

Frequently asked questions

Is Rocket Pharmaceuticals Inc (RCKT) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $1.27 versus a price of $2.39, about 47% lower (overvalued).
What is the fair value of RCKT?
Our model-based fair value for Rocket Pharmaceuticals Inc is $1.27 (as of Nov 7, 2026), built from audited fundamentals. The current price: $2.39.
What is the quality score of RCKT?
Rocket Pharmaceuticals Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rocket Pharmaceuticals Inc (RCKT)?
Our model-based price target is the fair value of $1.27 (as of Nov 7, 2026) from 1 valuation models. Cautious scenario $0.8400, optimistic scenario $1.59. It is a calculation from audited fundamentals, not an analyst target.
What is the Rocket Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $1.27, about 47% lower versus a price of $2.39 (overvalued). Cautious scenario $0.8400, optimistic scenario $1.59. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Rocket Pharmaceuticals Inc (RCKT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rocket Pharmaceuticals Inc it is $1.27 per share (as of Nov 7, 2026), against a price of $2.39. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Rocket Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, RCKT trades above its calculated fair value: price $2.39, fair value $1.27, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RCKT?
No. The price is what the market pays today ($2.39); the fair value is what the company's own numbers justify ($1.27). For Rocket Pharmaceuticals Inc the two are $1.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rocket Pharmaceuticals Inc worth?
The market values Rocket Pharmaceuticals Inc at about $273M (market capitalisation, as of Nov 7, 2026). Per share that is $2.39; our models calculate a fair value of $1.27 per share.
What do the bullish and bearish scenarios say about RCKT?
Our models span a range for Rocket Pharmaceuticals Inc: cautious scenario $0.8400, base $1.27, optimistic $1.59 per share (as of Nov 7, 2026, price $2.39). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rocket Pharmaceuticals Inc (RCKT)?
Balance-sheet figures for Rocket Pharmaceuticals Inc (as of Nov 7, 2026): return on equity −4.8%, debt of 0.13 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is RCKT from its 52-week high?
Rocket Pharmaceuticals Inc trades at $2.39, about 55% below its 52-week high of $5.30 and 9% above the low of $2.18 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.27 is for.
Which stocks are comparable to Rocket Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rocket Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $2.39, calculated fair value $1.27 (−47%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RCKT calculated?
We run Rocket Pharmaceuticals Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.27 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Rocket Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rocket Pharmaceuticals Inc (RCKT)?
The closing price on Nov 6, 2026 was $2.39. Our model-based fair value is $1.27, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rocket Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($1.59). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.8400 to $1.59) leaves room in how you read the outcome.

Key figures of Rocket Pharmaceuticals Inc

How large is the market capitalisation of Rocket Pharmaceuticals Inc (RCKT)?
The market capitalisation of Rocket Pharmaceuticals Inc is $273M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Rocket Pharmaceuticals Inc (RCKT)?
Earnings per share at Rocket Pharmaceuticals Inc are $−0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Rocket Pharmaceuticals Inc (RCKT)?
The return on equity (ROE) of Rocket Pharmaceuticals Inc is −4.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rocket Pharmaceuticals Inc (RCKT)?
On an EBIT basis the return on assets of Rocket Pharmaceuticals Inc is −48.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Rocket Pharmaceuticals Inc (RCKT) generate?
The free cash flow of Rocket Pharmaceuticals Inc is −$190M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rocket Pharmaceuticals Inc (RCKT) hold?
Rocket Pharmaceuticals Inc holds more cash than debt, $52.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Rocket Pharmaceuticals Inc in the live analysis

One click puts Rocket Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.